Abstract:Abstract INTRODUCTION Advanced therapies (ATs), such as adalimumab (ADA), infliximab (INF), golimumab (GOL), vedolizumab (VED), and ustekinumab (UST), referred to as biologics, are regularly used to treat moderate-to-severe ulcerative colitis (UC). Loss of response is a common problem with biologics in UC and one solution is to increase dose of biologics, affecting the cost of UC management. Assessing real-world dosing with biologics is important to inform the estimated treatment cost. The objective of this study was to assess the rate and magnitude of dose escalation with biologics in treatment of UC. METHODS This retrospective cohort study identified adult American patients in the IQVIA PharMetrics® Plus database who were diagnosed with UC and started an AT for UC between 01 Jan 2015 and 31 May 2021. Index date was the start date of a qualifying AT. Patients had ≥12 months of continuous pre- and post-index enrollment in a health plan, no claims for AT during the pre-index period, and no autoimmune diseases or indeterminate colitis. Rate and magnitude of dose escalation were assessed from the start of maintenance phase with AT until the end of follow-up period. Dose escalation was measured in first-line (1L) and second-line (2L) settings and defined as an increase in average dose ≥20% than expected dosing per FDA label during follow-up period after maintenance dose was reached. Dose escalations of ≥50% and ≥100% were also measured. RESULTS The study identified 5,997 UC patients starting an AT (1L setting) (median age, 40 years; 55.5% male; median follow-up, 27.5 [18.5-41.8] months), and 1,896 (31.6%) patients who received treatment with AT in a 2L setting. More patients reached maintenance dose in a 1L setting (86.6% [INF] to 92.7% [ADA]) than in a 2L setting (82.0% [INF] to 87.4% [ADA]). The rate of dose escalation in patients who reached maintenance dose for ADA, IFX, GOL, VED, UST was 22.0%, 17.9%, 7.0%, 28.8%, 50.6%, respectively, in a 1L setting, vs 21.9%, 19.2%, 7.7%, 25.9%, 55.1%, respectively, in a 2L setting (Figure 1). The frequency of dose escalation ≥50% varied for different therapies, 15.0% [ADA], 5.7% [IFX], 4.3% [GOL], 21.0% [VED], and 44.6% [UST] in a 1L setting vs 16.4% [ADA], 8.4% [IFX], 1.9% [GOL], 19.2% [VED], and 46.5% [UST] in a 2L setting (Figure 2). Dose escalation ≥100% was uncommon with both 1L therapies (0.4% [ADA] to 10.0% [VED]) and 2L therapies (0% [GOL] to 7.0% [VED]). CONCLUSIONS A meaningful percentage of ulcerative colitis patients treated with adalimumab, infliximab, vedolizumab, or ustekinumab had dose escalation regardless of line of treatment. Understanding the impact of these utilization patterns may inform real-world cost management. Figure 1 Rate of dose escalation with advanced therapies in ulcerative colitis Figure 2 Magnitude of dose escalation with advanced therapies in ulcerative colitis

P844 Frequency and effectiveness of dose de-escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA

DOP75 Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA

De-escalating therapy in inflammatory bowel disease: Results from an observational study in clinical practice

P702 Long term outcomes following de-escalation of dose-intensified ustekinumab in patients with Crohn’s disease

P912 A Real-World Evidence Study of Dose Escalation and associated costs of advanced therapies for Ulcerative Colitis in France and United Kingdom

SUBCUTANEOUS INFLIXIMAB (CT-P13 SC) DOSE ESCALATION AS AN OPTION FOR MANAGING THE LOSS OF RESPONSE IN INFLAMMATORY BOWEL DISEASE POST HOC ANALYSIS OF LIBERTY-UC AND LIBERTY-CD STUDY

REAL-WORLD RATE AND MAGNITUDE OF DOSE ESCALATION WITH BIOLOGICS IN PATIENTS WITH CROHN’S DISEASE

P916 Off-label dose escalation of Ustekinumab in Inflammatory Bowel Disease patients. Incidence rate, timing, dosing patterns and outcomes

P574 Clinical outcomes in extending of injection period of ustekinumab from every 8 to 12 weeks in patients with Crohn’s disease (CD-EXTEND Study)

P959 Dose escalated vedolizumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

P1012 Dose escalated Ustekinumab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

P751 Off-label dose escalation of Ustekinumab in Inflammatory Bowel Disease patients. Safety profil of different patterns

P679 Anti-TNF de-escalation following a treat-to-target strategy with golimumab therapy intensification to reach continuous clinical response in ulcerative colitis: the In-Target GETAID trial

Rates, Predictors, and Outcomes of Ustekinumab Dose Escalation in Inflammatory Bowel Disease

REAL-WORLD RATE AND MAGNITUDE OF DOSE ESCALATION WITH BIOLOGICS IN PATIENTS WITH ULCERATIVE COLITIS

P383 Real-life experience of the efficacy, safety and pharmacokinetic data of switching from intravenous to subcutaneous infliximab in inactive inflammatory bowel disease patients. Results from the ENEIDA registry

Real-World Rate And Magnitude Of Dose Escalation With Biologics In Patients With Crohn'S Disease

ASSESSING THE CLINICAL IMPACTS OF IMMUNOMODULATORY WITHDRAWAL FROM ANTI-TNF COMBINATION THERAPY IN PEDIATRIC INFLAMMTORY BOWEL DISEASE

P1005 Dose escalated Infliximab in Inflammatory Bowel Disease - Crohn's Colitis Cure (CCC) Data Insights Program

Subcutaneous infliximab cut-off points in patients with inflammatory bowel disease. Data from the ENEIDA registry

Evolution After Anti-TNF Discontinuation in Patients With Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study